Physician profile
Declan Kirk
NPI 1487277224
$1,513.89
in general payments reported to CMS, 2019-2025
10 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $165 · 2024: $470 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $935.80 | 2022-2025 | Clareon, Clareon Panoptix Pro, Acrysof Iq Vivity |
| Biotissue Holdings INC. | $169.37 | 2024-2025 | |
| Glaukos Corporation | $141.45 | 2023-2025 | Idosetr, Istent Infinite |
| Abbvie INC. | $77.95 | 2024-2025 | |
| Harrow Eye, LLC | $55.75 | 2024-2025 | Vevye |
| Rxsight INC | $41.04 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $29.58 | 2022 | |
| Dompe US, INC. | $23.46 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $21.27 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $18.22 | 2025 | Veritas Vision System, Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Declan Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.